152 related articles for article (PubMed ID: 15319242)
1. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).
Gervais R; Ducolone A; Breton JL; Braun D; Lebeau B; Vaylet F; Debieuvre D; Pujol JL; Tredaniel J; Clouet P; Quoix E
Ann Oncol; 2005 Jan; 16(1):90-6. PubMed ID: 15598944
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
[TBL] [Abstract][Full Text] [Related]
4. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
5. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.
Stemmler J; Mair W; Stauch M; Papke J; Deutsch G; Abenhardt W; Dorn B; Kentenich C; Malekmohammadi M; Jackisch C; Leinung S; Brudler O; Vehling-Kaiser U; Stamp J; Heinemann V
Oncology; 2005; 68(1):71-8. PubMed ID: 15809523
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
D'hondt R; Paridaens R; Wildiers H; Pauwelyn K; Thomas J; Dumez H; Van Oosterom AT
Anticancer Drugs; 2004 Apr; 15(4):341-6. PubMed ID: 15057137
[TBL] [Abstract][Full Text] [Related]
9. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.
Quoix E; Lebeau B; Depierre A; Ducolone A; Moro-Sibilot D; Milleron B; Breton JL; Lemarie E; Pujol JL; Brechot JM; Zalcman G; Debieuvre D; Vaylet F; Vergnenegre A; Clouet P
Ann Oncol; 2004 Jan; 15(1):38-44. PubMed ID: 14679117
[TBL] [Abstract][Full Text] [Related]
10. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Aihara T; Kim Y; Takatsuka Y
Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
[TBL] [Abstract][Full Text] [Related]
14. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Beuselinck B; Wildiers H; Wynendaele W; Dirix L; Kains JP; Paridaens R
Crit Rev Oncol Hematol; 2010 Jul; 75(1):70-7. PubMed ID: 19651523
[TBL] [Abstract][Full Text] [Related]
17. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M
Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
[TBL] [Abstract][Full Text] [Related]
20. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00).
Vázquez S; Grande C; Amenedo M; Fírvida JL; Lázaro M; Alonso G; Curiel T; Huidobro G; Mel JR; Ramos M
Anticancer Drugs; 2004 Jun; 15(5):489-94. PubMed ID: 15166623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
